ANDA 78171, held by Cipla. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 78171 (Levalbuterol Hydrochloride), held by Cipla, was first approved by FDA on Dec 13, 2013, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2013 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Dec 20, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 28, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 28, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 13, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters